Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Post by RalphRalphon Jul 16, 2019 8:01am
227 Views
Post# 29923817

Question regarding a potential Phase 3

Question regarding a potential Phase 3Obviously this is  completely dependent on positive results from this current trial.  That said, I've seen it mentioned that Phase 3 would span two years, with longer-term data readouts (I've seen 3 and 6 months mentioned).  Clearly, this would be a longer dosing period than the two week period utilized thus far.  

I am wondering:  given the seeming potency of ATB-346 and the fact that it has a much longer half-life than Naproxen alone, do you see any concern regarding longer-term dosing?  How large is the possibility that longer-term dosing could cause abnormally elevated liver enzymes or other complications?  Have any previous studies been done regarding consumption of H2S over an extended time frame?

I am not a pharmacology expert but have been wondering if the extended time frame of a potential Phase 3 presents any concerns regarding potency of the drug, the longer-than-normal half life of 346, and/or consistent H2S dosing.  I know that no one has a definitive answer, but I thought it might be worth discussing.
Bullboard Posts